Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07339423 · ClinicalTrials.gov registry record · Phase 3
AMAZE 1: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Lose Weight
A Phase 3 study of Obesity, sponsored by Novo Nordisk A/S.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 1,150
- Enrollment target
- 20
- Study locations
NCT07339423 is a Phase 3 study of Obesity that is actively recruiting participants, run by Novo Nordisk A/S. The registered enrollment target is 1,150 participants, above the 818-participant average among 1,053 other Obesity trials with a reported enrollment target (41% higher). The trial reports 20 study locations across 12 states.
The verdict
NCT07339423, a Phase 3 study of Obesity, is actively recruiting participants, sponsored by Novo Nordisk A/S.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,150 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this clinical study is to find out if NNC0487-0111 is safe and effective for treating people who have excess body weight. There are 2 study treatments in this study taken as injections under the skin once a week. Participants will either get NNC0487-0111 (the treatment being tested) or Placebo (a treatment that has no active medicine in it). Which treatment participants get is decided by chance.
Conditions Studied
Interventions
- DRUG NNC0487-0111
- DRUG Placebo (matched to NNC0487-0111)
Study Locations (20)
North Carolina
- UNC Eastowne Medical Office - Chapel Hill
- PharmQuest Life Sciences LLC - Greensboro
- Accellacare - Wilmington
South Carolina
- Medical Uni of SC Charleston - Charleston
- Coastal Carolina Research Ctr - North Charleston
- Hillcrest Clinical Research - Simpsonville
Texas
- Amarillo Medical Specialists - Amarillo
- Velocity Clinical Res-Dallas - Dallas
- Care United Research, LLC - Forney
Florida
- South Broward Research LLC - Miramar
- Clinical Neuroscience Solution - Orlando
Virginia
- Washington Cntr Weight Mgmt - Arlington
- Health Res of Hampton Roads - Newport News
Georgia
- Hope Clin Res & Wellness - Conyers
Illinois
- Endeavor Health - Skokie
Indiana
- Midwest Inst For Clin Res - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,150 participants |
| Start Date | 2026-02-24 |
| Est. Completion | 2029-08-21 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07339423
The ClinicalTrials.gov registry entry for NCT07339423 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 1,150 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 818-participant average among 1,053 other Obesity trials with a reported enrollment target (41% higher). The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Obesity appearing as the primary indexed condition, and to 2 interventions - of which NNC0487-0111 is the first listed.
NCT07339423 reports 20 study locations spanning 12 distinct geographic areas - top geographies include North Carolina, South Carolina, Texas.
Frequently Asked Questions
What is clinical trial NCT07339423 about?
NCT07339423 is a clinical study titled "AMAZE 1: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Lose Weight". The purpose of this clinical study is to find out if NNC0487-0111 is safe and effective for treating people who have excess body weight. There are 2 study treatments in this study taken as injections under the skin once a week. Participants will either get NNC0487-0111 (the treatment being tested) o...
What is the current status of trial NCT07339423?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 1,150 participants. The study started on 2026-02-24. Estimated completion is 2029-08-21.
What conditions does trial NCT07339423 study?
This clinical trial studies the following conditions: Obesity.
What interventions are being tested in trial NCT07339423?
The interventions under investigation include: NNC0487-0111 (DRUG), Placebo (matched to NNC0487-0111) (DRUG).
Who is sponsoring clinical trial NCT07339423?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07339423 being conducted?
This trial has 20 study locations across Florida, Georgia, Illinois, Indiana, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
RECRUITING · Phase 3
-
Efficacy and Safety of KAI-9531 Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes
RECRUITING · Phase 3
-
A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight
RECRUITING · Phase 3
-
A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes
RECRUITING · Phase 3
-
A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
RECRUITING · Phase 3
-
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.